EGFR and colorectal neoplasm: The demonstration that EGFR results abnormally expressed or upregulated in 50–80% of all cases of advanced colorectal tumours (Hemming et al, 1992; Kluftinger et al, 1992; Mayer et al, 1993) brought to the active development of anti-EGFR treatment strategies for these patients, including monoclonal antibodies, which target the extracellular domain of the EGFR and small molecules (tyrosine kinase inhibitors, TKIs), which target the tyrosine kinase domain of the receptor.